Insider buying last 90 days
$305Kin 2 open-market purchases
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 20 | DeLuca Teresa director | Purchase | $161K |
| Aug 19 | DeLuca Teresa director | Purchase | $144K |
From Form 4 filings, dated to when each was filed.
NASDAQ: SGRY
Surgery Partners (SGRY) Stock Analysis & Forecast
Oct 12 close
$14.24+0.35 (+2.5%)
Gekko Brief
AI summaryOct 12 closeSurgery Partners shares moved this week on the sale of its majority ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health, a deal advised by McDermott Will & Schulte and described by RBC as generating USD 587 million in net cash proceeds aimed primarily at debt reduction. Alongside the transaction, Cantor Fitzgerald reiterated an Overweight rating with an $18.00 price target, and RBC Capital reiterated an Outperform rating with a $19.00 target, even as the company's Q2 2026 results showed revenue beating forecasts alongside an adjusted loss.
SGRY closed at $14.24, up 2.5%, sitting just below both its 50-day average of $14.29 and its 200-day average of $14.46, with the 50-day below the 200-day. The GekkoIndex reads 57.9, placing the stock in the Neutral zone. Price stands 38.1% below Gekko Fair Value of $23.02.
Earnings are due 9 November 2026, 27 days out and before the open, landing inside a typical 20-trading-day holding period; the last report showed an EPS beat with an average absolute reaction of 8.4% historically. Over the last 90 days, insiders made 2 open-market purchases totaling $304,713. Consensus among 8 firms stands at 5 buy and 3 hold ratings, with a consensus target of $18.82. Seasonally, the next 20 trading days have averaged +7.7% over 5 years, rising in 4 of them.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Surgery Partners price vs fair value
Close $14.24200-day averageGekko Fair Value $23.02
Surgery Partners quick facts
- Market cap
- $1.86B
- P/E ratio
- —
- Forward P/E
- 18.9
- EPS, TTM
- −$0.69
- Revenue, TTM
- $3.37B
- Profit margin
- -2.6%
- Dividend yield
- —
- Beta
- 1.91
- Volume
- 1.21M avg 2.14M
- 1-year return
- −29.9%
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±8.3%
- 50-day average
- $14.29
- 200-day average
- $14.46
- Next earnings
- Nov 9 before open
- Shares outstanding
- 130.9M
Surgery Partners swing-trade checklist
Surgery Partners scores 3 supportive, 1 mixed and 2 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive1 mixed2 headwinds
- Trendheadwind
Below 50 and 200-day
Close $14.24 is below the 50-day ($14.29) and 200-day ($14.46) averages, and the 50-day is below the 200-day.
See the chart - GekkoIndexmixed
57.9, Neutral
Reading 57.9 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
38.1% below
Price is 38.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 90 days: 2 open-market insider purchases.
See smart money - Earnings riskheadwind
Reports in 28 days
Reports on Nov 9, 2026, 28 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.7% on average
From this point in the calendar, the next 20 trading days averaged +7.7% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Surgery Partners stock chart and price history
Surgery Partners closed at $14.24 on Oct 12, 2026, −29.9% over the past year, inside a 52-week range of $11.41 to $23.44.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −1.0%
- 3 months
- −5.8%
- 6 months
- +8.8%
- 1 year
- −29.9%
The full SGRY chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open SGRY in Gekko
Follow Surgery Partners through every session
Put SGRY on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track SGRY in GekkoFree for 7 days. No credit card required.
About Surgery Partners
Surgery Partners owns and runs a broad collection of surgical centers and related healthcare sites spread across the country. The company has built its name around ambulatory surgery centers and surgical hospitals that perform planned operations in areas like gastroenterology, general surgery, eye care, orthopedics, and pain treatment.
Its work is split into two parts, one covering the surgical facilities themselves and the other covering additional medical services. The hospitals also handle things such as imaging, pharmacy work, lab testing, maternity care, cancer treatment, physical therapy, and wound management, while the other segment brings together physician practices across several specialties, urgent care clinics, and anesthesia providers. Near the close of 2021, the company's holdings totaled 126 locations, split between 108 outpatient surgery centers and 18 surgical hospitals, reaching into 31 different states.
The company traces back to 2004 and runs its operations out of Brentwood, Tennessee. Investors can find its stock listed on the NASDAQ under the ticker SGRY.
- Listed
- NASDAQ
- Sector
- Health services
- Industry
- Hospital/Nursing management
- Website
- surgerypartners.com
Surgery Partners GekkoIndex: the smart money zone
Surgery Partners’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.9, in the Neutral zone, down 5.2 points over five sessions.
57.9Neutral
Down 5.2 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 45 | +2.9% | +3.1% | ||
| Accumulation | 287 | +0.4% | +1.2% | ||
| Neutral (current zone) | 328 | −1.5% | −4.8% | ||
| Distribution | 21 | −0.6% | −5.8% | ||
| Selling | 1 | Too few readings yet | |||
Average SGRY share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the SGRY price, zone by zone.Track SGRY in Gekko
Is Surgery Partners stock overvalued? Gekko Fair Value
Surgery Partners trades 38.1% below Gekko Fair Value of $23.02, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Surgery Partners shares are worth, recalculated every trading day.
$23.02
Gekko Fair Value, Oct 10, 2026
38.1% Undervalued
At the end of Aug 2026 the price was 21.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open SGRY in Gekko
Surgery Partners insider and Congress trading
Insiders filed 2 open-market purchases in Surgery Partners worth $305K, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in SGRY were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for SGRY, plotted on the chart in Gekko.Open SGRY in Gekko
Buybacks
Surgery Partners has been buying back its own shares.
- Latest authorization
- $200.0M, Mar 2, 2026
- Bought back, year ended Dec 31, 2018
- $2.00M
- As a share of market cap
- 0.11%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
0of the funds Gekko tracks hold SGRY.
0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko
Surgery Partners earnings: next date and track record
Surgery Partners reports on Nov 9, 2026, before the open (28 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 9, 2026
Expected before the open, 28 days away
- EPS estimate
- $0.12
- Revenue estimate
- $846.3M
4 of 8reports beat the EPS estimate
±8.4%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 10, 2026 AI summary
- What they said
- Surgery Partners reported Q2 2026 net revenue of ~$849M (+2.7% YoY) and adjusted EBITDA of ~$125M (14.7% margin), beating expectations. YTD revenue reached ~$1.66B (+3.6%) with EBITDA of ~$228M. Same-facility net revenue grew 5% driven by 4.8% rate improvement from higher-acuity procedures. The company announced sale of Idaho Falls hospital assets to Intermountain Health as a portfolio optimization to refocus on core short-stay surgical facilities. 191 new physicians recruited in Q2.
- Guidance
- Management reaffirmed full-year 2026 guidance following Q2 outperformance. Updated forward guidance will be provided upon closing of the Idaho Falls divestiture transaction. No specific revenue or earnings targets were revised in this excerpt.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 10, 2026 | $0.07 est −$0.03 | $848.9M est $830.0M | −3.4% |
| May 5, 2026 | −$0.03 est −$0.14 | $810.9M est $797.7M | +2.7% |
| Mar 2, 2026 | $0.12 est $0.31 | $885.0M est $866.8M | −10.2% |
| Nov 10, 2025 | $0.13 est $0.19 | $821.5M est $866.5M | −26.7% |
| Aug 5, 2025 | $0.17 est $0.16 | $826.2M est $823.5M | +0.9% |
| May 12, 2025 | $0.04 est $0.05 | $776.0M est $777.1M | +3.5% |
| Mar 3, 2025 | $0.44 est $0.38 | $864.4M est $800.1M | −1.2% |
| Nov 12, 2024 | −$0.25 est $0.25 | $770.4M est $829.0M | −18.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Surgery Partners stock forecast and analyst price targets
Analysts’ average 12-month price target for Surgery Partners is $18.82, +32.2% from the last close, from 8 firms rating the stock in the last 90 days.
$18.82consensus 12-month target, +32.2% from the last close
Now $14.24Avg $18.82
Low $14High $24
Each firm’s latest rating in the last 90 days: 8 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 7 | Barclays | $14 | −1.7% |
| Sep 29 | RBC Capital | $19 | +33.4% |
| Sep 18 | Bank of America Securities | $20 | +40.4% |
| Sep 18 | TD Cowen | $19 | +33.4% |
| Sep 14 | J.P. Morgan | $15 | +5.3% |
−4.8%average 20-day move after past Neutral readings
+7.7%average move over the next 20 trading days in the last 5 years
±4.3%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Surgery Partners seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Surgery Partners averaged +7.7% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +4.7% | 4 of 5 |
| Next 10 trading days | +4.9% | 4 of 5 |
| Next 15 trading days | +2.2% | 3 of 5 |
| Next 20 trading days | +7.7% | 4 of 5 |
| Next 30 trading days | −0.3% | 3 of 5 |
For scale, SGRY’s typical 20-trading-day move in either direction is about 8.3%.
Surgery Partners market cap and key statistics
Surgery Partners’s market cap is $1.86B and revenue of $3.37B over the last twelve months.
Valuation
- Market cap
- $1.86B
- Forward P/E
- 18.9
- EPS, TTM
- −$0.69
- Gekko Fair Value
- $23.02
Trading
- Volume
- 1.21M
- Avg volume, 20 days
- 2.14M
- 52-week high
- $23.44
- 52-week low
- $11.41
- Shares outstanding
- 130.9M
Financials
- Revenue, TTM
- $3.37B
- Profit margin
- -2.6%
- Return on equity
- 2.3%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 1.91
- Typical daily move
- ±4.3%
- Typical 20-day move
- ±8.3%
Surgery Partners stock news this week
Coverage of Surgery Partners this week reads positive: 4 positive, 2 neutral and 0 negative headlines.
- McDermott Will & Schulte advises Surgery Partners on sale of ownership interests in Idaho Falls facilitiesMcDermott Will & Schulte, Oct 8
- Surgery Partners stock gains 2.24 percent with Cantor at OverweightAD HOC NEWS, Oct 8
- Cantor Fitzgerald reiterates Surgery Partners stock Overweight rating By Investing.comInvesting.com Nigeria, Oct 7
- RBC reiterates target for Surgery Partners stock at USD 19.00AD HOC NEWS, Oct 7
- Why Surgery Partners (SGRY) Is Back In The SpotlightSimply Wall Street, Oct 6
- Cantor Fitzgerald reiterates Surgery Partners stock Overweight ratingInvesting.com, Oct 6
Surgery Partners peers
Surgery Partners’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| HCAHCA Healthcare | Neutral | 18.9% above |
| THCTenet Healthcare | Neutral | 6.7% below |
| UHSUniversal Health Services | Neutral | 21.4% below |
| PACSPACS | Neutral | 11.0% below |
| CHEChemed | Accumulation | 7.7% below |
| NHCNational HealthCare | Neutral | 30.5% above |
A peer links to its own page where one exists.
Surgery Partners stock FAQ
What is Surgery Partners’s market cap?
Surgery Partners’s market cap is $1.86B at the Oct 12, 2026 close of $14.24, with 130.9M shares outstanding.
What is the Surgery Partners stock forecast?
The consensus analyst 12-month price target for Surgery Partners is $18.82, +32.2% from the last close. Of the 8 firms that rated the stock in the last 90 days, 5 rate it a buy, 3 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Surgery Partners stock overvalued or undervalued?
On Gekko’s estimate Surgery Partners is undervalued: the Oct 12, 2026 close of $14.24 is 38.1% below Gekko Fair Value of $23.02. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Surgery Partners report earnings next?
Surgery Partners is expected to report on Nov 9, 2026, before the market opens (28 days away). Analysts expect earnings of $0.12 per share on revenue of $846.3M. Surgery Partners beat the earnings estimate in 4 of its last 8 reports, moving 8.4% on average across the report.
What is Surgery Partners’s 52-week high and low?
Surgery Partners’s 52-week high is $23.44 and its 52-week low is $11.41; it closed at $14.24 on Oct 12, 2026, −29.9% over the past year. Over the last five years the shares peaked at $63.87 on Apr 21, 2022.
Is Surgery Partners stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (fair value, smart money and seasonality), 1 as mixed (gekkoindex) and 2 as headwinds (trend and earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Surgery Partners the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.